羟氯喹对 COVID-19 非重症住院患者 SARS-CoV-2 病毒载量降低没有益处。
No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19.
机构信息
Department of Medicine, Discipline of Infectious Diseases, Laboratório de Virologia Clínica, Universidade Federal de São Paulo, Rua Pedro de Toledo, 781 - Vila Clementino, São Paulo, SP, 04039-032, Brazil.
Hospital São Paulo, Universidade Federal de São Paulo, São Paulo, Brazil.
出版信息
Braz J Microbiol. 2020 Dec;51(4):1765-1769. doi: 10.1007/s42770-020-00395-x. Epub 2020 Oct 27.
BACKGROUND
Some studies have shown that hydroxychloroquine (HCQ) is an effective drug in reducing the in vitro replication of SARS-CoV-2. However, the in vivo effect of HCQ still unclear.
OBJECTIVES
This study aims to evaluate viral load clearance in patients with COVID-19 who underwent HCQ treatment in comparison with a control group that did not receive the drug.
STUDY DESIGN
This prospective study comprised consecutive viral load measurements in patients with COVID-19 hospitalized with a moderate illness. Patients received 400 mg of HCQ every 12 h for 10 days according to the medical decision. Nasal swab samples were collected from patients during early, intermediary, and final clinical stage of COVID-19.
RESULTS
A total of 155 samples were collected from 66 patients with COVID-19 (60% female), with a median age of 58 years. The viral load between studied groups, assumed as a semiquantitative measure of cycle threshold (Ct) values, presented no significant difference within the three consecutive measures (ΔCt) (p > 0.05). We also analyzed the ΔCt viral load at different intervals of sample collection (Δt < 7; 7-12; and > 12 days) without significant differences at any ΔCt (p > 0.05).
CONCLUSION
In this study, we did not observe any change in viral load reduction in vivo with the use of HCQ.
背景
一些研究表明羟氯喹（HCQ）是一种有效药物，可减少 SARS-CoV-2 的体外复制。然而，HCQ 的体内作用尚不清楚。
目的
本研究旨在评估 COVID-19 患者接受 HCQ 治疗与未接受药物治疗的对照组相比，病毒载量清除情况。
研究设计
这是一项前瞻性研究，纳入了因中度疾病住院的 COVID-19 患者的连续病毒载量测量。根据医疗决策，患者接受 400mg HCQ 每日 2 次，共 10 天。在 COVID-19 的早期、中期和终末期，从患者中采集鼻拭子样本。
结果
共从 66 名 COVID-19 患者（60%为女性）中采集了 155 个样本，中位年龄为 58 岁。研究组之间的病毒载量（假设为循环阈值（Ct）值的半定量测量）在连续 3 次测量（ΔCt）中没有显著差异（p＞0.05）。我们还分析了不同样本采集时间间隔（Δt＜7；7-12；和＞12 天）的 ΔCt 病毒载量，在任何 ΔCt 时均无显著差异（p＞0.05）。
结论
在本研究中，我们未观察到使用 HCQ 体内病毒载量降低有任何变化。
Zotero 插件